Moderna Inc. (MRNA)
NASDAQ
Biotech
mRNA
Investment Thesis
Moderna built the world’s most advanced mRNA drug factory. Post-COVID, they are deploying that platform across cancer vaccines, respiratory viruses (RSV, flu), rare diseases, and HIV. The personalised cancer vaccine (mRNA-4157) with Merck’s Keytruda showed 49% reduction in recurrence in melanoma — a potential paradigm shift in oncology.
Key Drivers
- Cancer Vaccine Platform: mRNA-4157 personalised cancer vaccine — each patient gets a unique therapy targeting their specific tumour mutations.
- Pipeline Breadth: 45+ programs in development across therapeutic areas — diversified platform bet.
- Manufacturing Scale: Largest mRNA manufacturing capacity globally; supply agreements with governments and pharma partners.
Risk Factors
- Post-COVID Revenue Cliff: COVID vaccine revenue collapsed; pipeline must deliver before cash depletes.
- Competition: BioNTech is advancing similar cancer vaccine programs (BNT111, BNT122).